Evaluation of Effectiveness of a New Kit of Reagents for Detection of Mutations Associated with Drug Resistance of Tuberculous Mycobacteria to Rifampicin and Isoniazid, by PCR according to Evidences of Clinical Trials

The objective: to evalute effectiveness in clinical trials of the new kit of reagents of AmpliTest® MBT-Resist-I based on real-time PCR (RT-PCR) versus similar kits of reagent registered in Russia, to identify genetic markers of M. tuberculosis complex (MTB) resistance to rifampicin (RIF) and isonia...

Full description

Saved in:
Bibliographic Details
Main Authors: Yu. L. Mikulovich, Yu. A. Savochkina, A. I. Zaytseva, A. E. Panova, A. S. Vinokurov, G. A. Shipulin
Format: Article
Language:Russian
Published: New Terra Publishing House 2023-08-01
Series:Туберкулез и болезни лёгких
Subjects:
Online Access:https://www.tibl-journal.com/jour/article/view/1744
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849771246292566016
author Yu. L. Mikulovich
Yu. A. Savochkina
A. I. Zaytseva
A. E. Panova
A. S. Vinokurov
G. A. Shipulin
author_facet Yu. L. Mikulovich
Yu. A. Savochkina
A. I. Zaytseva
A. E. Panova
A. S. Vinokurov
G. A. Shipulin
author_sort Yu. L. Mikulovich
collection DOAJ
description The objective: to evalute effectiveness in clinical trials of the new kit of reagents of AmpliTest® MBT-Resist-I based on real-time PCR (RT-PCR) versus similar kits of reagent registered in Russia, to identify genetic markers of M. tuberculosis complex (MTB) resistance to rifampicin (RIF) and isoniazid (INH) in human biological samples and MTB cultures.Subjects and Methods. 200 DNA samples were studied, they had been obtained from biological specimens (sputum (N=100), bronchoalveolar lavage (N=50), biopsy (surgical material; N=50)) of pulmonary tuberculosis patients and containing MTB DNA at a concentration of at least 1 x 103 GE/ml, and from 100 DNA samples of MTB cultures. Efficiency of detecting mutations associated with MTB resistance to RIF and INH using the new kit of reagent of AmpliTest® MBT-Resist-I was evaluated in comparison with HP Amplitube-MDR-RV (OOO Sintol, Russia). In the case of discordant results, the target MTB DNA loci were sequenced by Sanger.Results. We observed complete agreement of the results and consequently high efficiency rates (positive and negative concordance of results - 100%, respectively) of the new kit of reagents of AmpliTest® MBT-Resist-I in comparison with the kit of reagent of Amplitube-MDR-RV in detection of mutations associated with MTB resistance to both RIF and INH, both for human samples and for MTB cultures. In two DNA samples of MTB cultures, an additional mutation (I572L) in the rpoB gene was detected using the new kit of reagents which was not detected by the comparison kit and was confirmed by Sanger sequencing.Conclusion. Inhalers vary significantly by the patients' ability to use them correctly. Asthma patients master the correct inhalation technique better versus COPD patients. Liquid inhalers were more difficult to be used correctly, and the best results were observed with multi-dose powder inhalers. The patient's training by a healthcare professional is critical to assure the correct use of inhalers.
format Article
id doaj-art-f91e7eeffc284b4abc6decef81079b6a
institution DOAJ
issn 2075-1230
2542-1506
language Russian
publishDate 2023-08-01
publisher New Terra Publishing House
record_format Article
series Туберкулез и болезни лёгких
spelling doaj-art-f91e7eeffc284b4abc6decef81079b6a2025-08-20T03:02:41ZrusNew Terra Publishing HouseТуберкулез и болезни лёгких2075-12302542-15062023-08-011014465510.58838/2075-1230-2023-101-4-46-551739Evaluation of Effectiveness of a New Kit of Reagents for Detection of Mutations Associated with Drug Resistance of Tuberculous Mycobacteria to Rifampicin and Isoniazid, by PCR according to Evidences of Clinical TrialsYu. L. Mikulovich0Yu. A. Savochkina1A. I. Zaytseva2A. E. Panova3A. S. Vinokurov4G. A. Shipulin5Center for Strategic Planning and Management of Biomedical Health Risks, Russian Federal Medical Biological AgencyCenter for Strategic Planning and Management of Biomedical Health Risks, Russian Federal Medical Biological AgencyCenter for Strategic Planning and Management of Biomedical Health Risks, Russian Federal Medical Biological AgencyNational Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of HealthNational Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of HealthCenter for Strategic Planning and Management of Biomedical Health Risks, Russian Federal Medical Biological AgencyThe objective: to evalute effectiveness in clinical trials of the new kit of reagents of AmpliTest® MBT-Resist-I based on real-time PCR (RT-PCR) versus similar kits of reagent registered in Russia, to identify genetic markers of M. tuberculosis complex (MTB) resistance to rifampicin (RIF) and isoniazid (INH) in human biological samples and MTB cultures.Subjects and Methods. 200 DNA samples were studied, they had been obtained from biological specimens (sputum (N=100), bronchoalveolar lavage (N=50), biopsy (surgical material; N=50)) of pulmonary tuberculosis patients and containing MTB DNA at a concentration of at least 1 x 103 GE/ml, and from 100 DNA samples of MTB cultures. Efficiency of detecting mutations associated with MTB resistance to RIF and INH using the new kit of reagent of AmpliTest® MBT-Resist-I was evaluated in comparison with HP Amplitube-MDR-RV (OOO Sintol, Russia). In the case of discordant results, the target MTB DNA loci were sequenced by Sanger.Results. We observed complete agreement of the results and consequently high efficiency rates (positive and negative concordance of results - 100%, respectively) of the new kit of reagents of AmpliTest® MBT-Resist-I in comparison with the kit of reagent of Amplitube-MDR-RV in detection of mutations associated with MTB resistance to both RIF and INH, both for human samples and for MTB cultures. In two DNA samples of MTB cultures, an additional mutation (I572L) in the rpoB gene was detected using the new kit of reagents which was not detected by the comparison kit and was confirmed by Sanger sequencing.Conclusion. Inhalers vary significantly by the patients' ability to use them correctly. Asthma patients master the correct inhalation technique better versus COPD patients. Liquid inhalers were more difficult to be used correctly, and the best results were observed with multi-dose powder inhalers. The patient's training by a healthcare professional is critical to assure the correct use of inhalers.https://www.tibl-journal.com/jour/article/view/1744copddrug resistant mtbgenetic markers of resistancerifampicinisoniazidreal-time pcr
spellingShingle Yu. L. Mikulovich
Yu. A. Savochkina
A. I. Zaytseva
A. E. Panova
A. S. Vinokurov
G. A. Shipulin
Evaluation of Effectiveness of a New Kit of Reagents for Detection of Mutations Associated with Drug Resistance of Tuberculous Mycobacteria to Rifampicin and Isoniazid, by PCR according to Evidences of Clinical Trials
Туберкулез и болезни лёгких
copd
drug resistant mtb
genetic markers of resistance
rifampicin
isoniazid
real-time pcr
title Evaluation of Effectiveness of a New Kit of Reagents for Detection of Mutations Associated with Drug Resistance of Tuberculous Mycobacteria to Rifampicin and Isoniazid, by PCR according to Evidences of Clinical Trials
title_full Evaluation of Effectiveness of a New Kit of Reagents for Detection of Mutations Associated with Drug Resistance of Tuberculous Mycobacteria to Rifampicin and Isoniazid, by PCR according to Evidences of Clinical Trials
title_fullStr Evaluation of Effectiveness of a New Kit of Reagents for Detection of Mutations Associated with Drug Resistance of Tuberculous Mycobacteria to Rifampicin and Isoniazid, by PCR according to Evidences of Clinical Trials
title_full_unstemmed Evaluation of Effectiveness of a New Kit of Reagents for Detection of Mutations Associated with Drug Resistance of Tuberculous Mycobacteria to Rifampicin and Isoniazid, by PCR according to Evidences of Clinical Trials
title_short Evaluation of Effectiveness of a New Kit of Reagents for Detection of Mutations Associated with Drug Resistance of Tuberculous Mycobacteria to Rifampicin and Isoniazid, by PCR according to Evidences of Clinical Trials
title_sort evaluation of effectiveness of a new kit of reagents for detection of mutations associated with drug resistance of tuberculous mycobacteria to rifampicin and isoniazid by pcr according to evidences of clinical trials
topic copd
drug resistant mtb
genetic markers of resistance
rifampicin
isoniazid
real-time pcr
url https://www.tibl-journal.com/jour/article/view/1744
work_keys_str_mv AT yulmikulovich evaluationofeffectivenessofanewkitofreagentsfordetectionofmutationsassociatedwithdrugresistanceoftuberculousmycobacteriatorifampicinandisoniazidbypcraccordingtoevidencesofclinicaltrials
AT yuasavochkina evaluationofeffectivenessofanewkitofreagentsfordetectionofmutationsassociatedwithdrugresistanceoftuberculousmycobacteriatorifampicinandisoniazidbypcraccordingtoevidencesofclinicaltrials
AT aizaytseva evaluationofeffectivenessofanewkitofreagentsfordetectionofmutationsassociatedwithdrugresistanceoftuberculousmycobacteriatorifampicinandisoniazidbypcraccordingtoevidencesofclinicaltrials
AT aepanova evaluationofeffectivenessofanewkitofreagentsfordetectionofmutationsassociatedwithdrugresistanceoftuberculousmycobacteriatorifampicinandisoniazidbypcraccordingtoevidencesofclinicaltrials
AT asvinokurov evaluationofeffectivenessofanewkitofreagentsfordetectionofmutationsassociatedwithdrugresistanceoftuberculousmycobacteriatorifampicinandisoniazidbypcraccordingtoevidencesofclinicaltrials
AT gashipulin evaluationofeffectivenessofanewkitofreagentsfordetectionofmutationsassociatedwithdrugresistanceoftuberculousmycobacteriatorifampicinandisoniazidbypcraccordingtoevidencesofclinicaltrials